INTRODUCTION
Diarrhea ,a biggest infant killer worldwide specially in developing countries like India, Nepal, Bangladesh and Shrilanka , where a child suffers on an average 3-6 episodes of diarrhea in first year of life claiming death rate of 20-60/thousand children annually. Interaction between diarrheal disease and nutritional status are complex and synergistic and serious issues globally., as they affect thousands of millions of young children every year and causes >3 millions death of children < 5yrs in spite of intensive filed based diagnosis and treatment , 1,2 usually 109 of every 1000 children dies before 5 yrs (Unicef report 2012) and 11% death is due to diarrhea, present deth rate of 38 per thousand in India to be achieved by 2015 ,though diarrheal death dropped in India Usually child loses water and electrolyte alike adult due to fairly large area of secreting intestinal mucosa 7 .
The commonest cause of during infancy is virus (Rotavirus) or non specific though diarrheas significantly alter nutrition but simultaneously malnutrition also predisposes diarrhea due to declined immune response and aggravated secretory function of intestinal mucosa.
As during infancy the major cause of diarrhea is increased secretion due to increased cyclic AMP during dentition phase or due to organismal toxin 2 . Inspite of its non bacterial pathogenesis, the commonly prescribed preparation constituting even contra indicated antimicrobial agent (Quinolone) combination is quite in vogue and prescribed by qualified and specialized clinician, which not only causes therapy related untoward effect but also presents with manifestation of super infection egcandidiasis, fungal diarrhea, urinary tract infectionand mucous colitis are in vogue (even containing contraindicated molecules), which not only cause various therapeutic hazards like post diarrhea mucous colitis, urinary tract infection, fungal super infection and mortality due to post diarrhea dehydration and encephalopathy 7 .
Hence considering the mortality and morbidity in infants due to altered secretory and absorptive mechanism of intestinal mucosa, a clinical study to evaluate an anti secretory prodrug RACECADOTRIL in declining the secretion of intestinal mucosa and promotion of fluid and electrolyte transport in changing the consistency and frequency of stool and safety profile in infant diarrhea is planned
MATERIALS AND METHODS

Design and Study
Comparative clinical study to evaluate RACECADOTRIL orally in limiting fluid and electrolyte loss in infant diarrhea. 
Patients
Method
After proper knowledge regarding the proposed study written consent of the parent was taken and selected infants were duly examined and patient's informants (parent or attendant) were interrogated thoroughly for frequency, consistency and odor of stool ,therapeutics taken and their effects and mode and type of feedings.
Patients were also assessed for their hydration and thermal state. Dehydration state was assessed as per following index of assessment. Selected patients were investigated for serum electrolyte, stool routine and culture, urine routine and culture was duly done.
Selected patients were classified into two groups constituting equal number of infants of similar status to adjudge the comparative therapeutic status of RACECADOTRIL in infant diarrhea. In order to check or induce paralysis or neuritis in suspected cases of viral diarrhea as a precautionary measure intramuscular injections been duly avoided. Among the anti diarrheal recommended are Nitazoxnide dry syrup and Co -trimoxazole suspension in recommended therapeutic dose. Racecadotril powder was recommended in dose of 1.5mg/Kg every 8 hours with palatable water/Oral Rehydration Solution. Irrespective of the nutritional status and infant feeding type ,infant's mother were advised to feed their child on barley or rice water gruel for 72 hours to avoid a risk of lactose intolerance and milk or food induced intestinal cramps or agony.
Each mother or parent were given a follow up card to enter the following -Frequency of lose motion every day 
OBSERVATIONS
Among the selected infants, majorities (39%) were of age group 6-9 months and 17% were of age group 3-6 months. 32% infants had frequency of motion 4-6 every 24 hours while 19% shows >13 every 24 hours.( T-1)
Table1. Distribution of patients as per their age, sex and frequency of motion
Age group
Number of patients Frequency of motion/24hr 4-6 7-9 10-12 3 months  50  46  56  40  32  20  42  30  3-6 months  60  48  46  35  30  22  32  25  6-9 months  120  89  110  78  94  68  76  45  9-12months  80  60  75  55  60  47  51  38  310  243 287  208  216  157  201  138 Out of all 65% (1136) infants present with lose watery motion, 23% and 12% infants had greenish lose motion and lose motion with mucous and froth respectively, 85% had fever and 80% presented with scanty urine(T-2). Male  Female  Total  Lose watery motion  714  422  1136  Lose greenish motion  190  213  403  Lose motion with froth  110  111  221  Abdominal distension  880  530  1410  Prone lying  912  625  1537  Irritability  1006  703  1709  Scanty urine  718  698  1416  Depressed anterior fontanelle  886  526  1412  Fever  846  649  1495 Not only this short duration of diseases check untoward effects as revealed by unaltered hematological , hepatic and renal function. Early change in consistency and decline in frequency of lose motion and loss of fluid and electrolytes in infants taking Racecadotril can be explained asRacecadotril, a pro drug which gets hydrolyzed to THIORPHAN and inhibits intestinal encaphalin ( a membrane bound metalo peptidase) and prolong the anti secretory effect of encaphalin resulting in reduced secretion of water and electrolyte in the intestinal lumen, ultimately declining the intestinal load and intestinal stretch receptor response , finally reduce stretch ,stimulation of the intestinal musculature leading to decline in tenesmus and defecation response.
Table2. Distribution of patients as per clinical presentation
Particulars
Number of patients
Without increasing intestinal transit time and promoting bacterial colonization or fluid pooling in the distended bowel lumen or causing constipation
CONCLUSION
RACECADOTRIL, an anti secretory prodrug prolongs the anti secretory effect of encephalin decreases the intestinal over load ,promote water and electrolyte absorption and help change the consistency of stool ,checks water and electrolyte loss and cut short both the duration and cost of therapy.
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